• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Leucine-rich repeat-containing protein 17 (LRRC17)

ACP14884

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP14884 Target NameLRRC17
Target SynonymsLRRC17; P37NB; UNQ3076/PRO9909; Leucine-rich repeat-containing protein 17; p37NBFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range19-441
Protein LengthFull Length of Mature ProteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ8N6Y2
Background Information
  • Uniprot Id

    Q8N6Y2

  • Target Species

    Human

  • Target Name

    LRRC17

  • Target Full Name

    Leucine-rich repeat-containing protein 17

  • Target Function

    Involved in bone homeostasis. Acts as a negative regulator of RANKL-induced osteoclast precursor differentiation from bone marrow precursors.

  • Target Subcellular Location

    Secreted, extracellular space.

  • Target Tissue Specificity

    Expressed in osteoblast cell lines. Well expressed in ovary, heart, pancreas, skeletal muscle, lung, and fetal kidney and lung and only at the basal levels in the other tissues examined including adult kidney. More expressed in S-type neuroblastoma cells

  • Target Research Area

    Signal Transduction

  • Target Synonyms

    LRRC17; P37NB; UNQ3076/PRO9909; Leucine-rich repeat-containing protein 17; p37NB

Inquire Recombinant Human Leucine-rich repeat-containing protein 17 (LRRC17) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification